Reversal of Neuromuscular Blockade with Sugammadex Based on the Residual of Rocuronium in the Body

Reversal of Neuromuscular Blockade with Sugammadex Based on the Residual of Rocuronium in the Body - Reversal of Neuromuscular Blockade with Sugammadex Based on the Residual of Rocuronium in the Body

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000017126

Enrollment

120

Registered

2015-04-13

Start date

2013-11-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Patients scheduled for elective surgery requiring general anesthesia

Interventions

the group in which sugammadex are administered 2mg/kg the group in which sugammadex are administered 4 times the residual amount of rocuronium the group in which sugammadex are administered 6 times th

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: the patients scheduled for elective surgery requiring general anesthesia the patients were ASA physical status 1-2

Exclusion criteria

Exclusion criteria: the patients were ASA physical status 3-4 the patients who have cardiac, hepatic, renal or neuromuscular disorders the patients who are scheduled hepatic or renal surgery

Design outcomes

Primary

Measure	Time frame
Evaluation of neuromuscular responses with a peripheral neurostimulator	—

Countries

Japan

Contacts

Public ContactTomotaka Morita

Osaka University Graduate School of Medicine Department of Anesthesiology and Intensive Care

tmorita@anes.med.osaka-u.ac.jp+81-6-6879-3133

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026